CERo Therapeutics Holdings ( (CERO) ) has released a notification of late filing.
Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
CERo Therapeutics Holdings, Inc. has announced a delay in filing its Form 10-Q (Quarter Report) for the financial period ending September 30, 2025. The delay is primarily due to the finalization of accounting for recent transactions, including the issuance of Series E Preferred Stock and conversions related to Series D Preferred Stock. The company’s independent auditors are also completing their review. CERo Therapeutics expects to submit the report within five calendar days following the original due date. Preliminary financial results indicate a net loss of $4.4 million for the quarter, with notable changes in research and development expenses and deemed dividends. These figures are subject to change upon completion of the reporting process. The notification was signed by Andrew Kucharchuk, the Chief Financial Officer, who emphasized ongoing compliance efforts.
The most recent analyst rating on (CERO) stock is a Hold with a $0.10 price target. To see the full list of analyst forecasts on CERo Therapeutics Holdings stock, see the CERO Stock Forecast page.
More about CERo Therapeutics Holdings
Average Trading Volume: 1,768,678
Technical Sentiment Signal: Sell
Current Market Cap: $107.3K
See more data about CERO stock on TipRanks’ Stock Analysis page.